Clinical Trial

DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is conducted to evaluate the efficacy and safety of transarterial chemoembolization with drug-eluting beads (DEB-TACE) combined with hepatic artery infusion chemotherapy (HAIC) with oxaliplatin and raltitrexed (RALOX-HAIC) versus DEB-TACE alone for unresectable large hepatocellular carcinoma (HCC).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-04-29; most recent amendment 2025-02-18.
Status change: Not Yet Recruiting → Recruiting 2024-05-05
Trial Details
NCT Number NCT06397235
Lead Sponsor Second Affiliated Hospital of Guangzhou Medical University
Collaborators: Zhongshan People's Hospital, Guangdong, China, Guangzhou Development District Hospital, The Affiliated Shunde Hospital of Jinan University
Conditions Hepatocellular Carcinoma Non-resectable
Enrollment 130 participants
Start Date 2024-05-01
Primary Completion 2027-04-30 (estimated)
Study Completion 2028-04-30 (estimated)
Updated on ClinicalTrials.gov 2025-02-20